Shanghai Rightongene Biotechnology Co.Ltd(688217) (SH Shanghai Rightongene Biotechnology Co.Ltd(688217) , closing price: 49.16 yuan) according to the annual performance report released on April 19, the operating revenue in 2021 was about 291 million yuan, a year-on-year increase of 2.11%; The net profit attributable to the shareholders of the listed company was about 47.33 million yuan, a year-on-year increase of 22.26%; The basic earnings per share was 0.95 yuan, a year-on-year increase of 2.15%. It is proposed not to distribute cash, give bonus shares or convert to growth.
From January to December 2020, Shanghai Rightongene Biotechnology Co.Ltd(688217) ‘s operating revenue was composed of: blood diseases accounted for 49.6%, testing services accounted for 12.28%, solid tumors accounted for 11.02%, purchased reagents accounted for 8.21%, other businesses accounted for 6.97%, and scientific research services accounted for 6.11%.
Shanghai Rightongene Biotechnology Co.Ltd(688217) ‘s chairman and general manager are Xiong Hui, female, 50 years old, with a doctorate background.
